Icanbelimod
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM) . Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis) . Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
Product Specifications
CAS Number
1514888-56-2
Product Name Alternative
S1p receptor agonist 1
UNSPSC
12352005
Target
LPL Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/icanbelimod.html
Concentration
10mM
Purity
99.90
Solubility
DMSO : 6.8 mg/mL (ultrasonic; warming)
Smiles
O=C(C1CN(CC2=CC=C(C3=NOC(C4=CC=C(CC(C)C)C=C4)=N3)C=C2F)C1)O
Molecular Formula
C23H24FN3O3
Molecular Weight
409.45
References & Citations
[1]Zhenwei, et al. Immune adjustment compound, use thereof and pharmaceutical composition comprising same. Patent WO2015039587A1
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SOX4 (Master Regulator of Epithelial-Mesenchymal Transition) (SOX4/2540), CF405S conjugate, 0.1mg/mL
3-Hydroxybutanoic Acid + 3-(3-Hydroxybutyryloxy)butyric Acid (CAS:7565-79-9) (50:50 Mixture)
